Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase II single-arm clinical trial.
Li TuWei-Han ZhangLu NiZihan XuKun YangHong-Feng GouQing ZhuMing LiuYu YangJian-Kun HuMeng QiuPublished in: Cancer medicine (2022)
Intraperitoneal high-dose paclitaxel with systemic SOX is an effective and tolerable first-line treatment for patients with peritoneal metastatic gastric cancer and patients with sPCI≤12 scores might be recommended crowd for this regimen as conversion therapy.